Celyad slides on Phase III heart failure miss

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said cell therapy C-Cure missed the primary endpoint in the Phase III CHART-1 study to treat ischemic heart failure. The

Read the full 243 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE